欢迎来到《四川大学学报(医学版)》

儿童弥漫性肺实质疾病/肺间质疾病诊治现状与挑战

陈慧中

陈慧中. 儿童弥漫性肺实质疾病/肺间质疾病诊治现状与挑战[J]. 四川大学学报(医学版), 2021, 52(5): 721-724. doi: 10.12182/20210960101
引用本文: 陈慧中. 儿童弥漫性肺实质疾病/肺间质疾病诊治现状与挑战[J]. 四川大学学报(医学版), 2021, 52(5): 721-724. doi: 10.12182/20210960101
CHEN Hui-zhong. Current Status of and Challenges in Diagnosis and Treatment of Childhood Diffuse Parenchymal Lung Diseases/Childhood Interstitial Lung Diseases[J]. JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCE EDITION), 2021, 52(5): 721-724. doi: 10.12182/20210960101
Citation: CHEN Hui-zhong. Current Status of and Challenges in Diagnosis and Treatment of Childhood Diffuse Parenchymal Lung Diseases/Childhood Interstitial Lung Diseases[J]. JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCE EDITION), 2021, 52(5): 721-724. doi: 10.12182/20210960101

栏目: 专家笔谈

儿童弥漫性肺实质疾病/肺间质疾病诊治现状与挑战

doi: 10.12182/20210960101

Current Status of and Challenges in Diagnosis and Treatment of Childhood Diffuse Parenchymal Lung Diseases/Childhood Interstitial Lung Diseases

  • 摘要: 经过多年的努力奋斗,我国医学领域在儿童弥漫性肺实质疾病/肺间质疾病(childhood diffuse parenchymal lung diseases/childhood interstitial lung diseases, chDPLD/chILD)的专业理论和临床实践方面取得了可喜的进步,但也面临诸多问题和挑战。我们必须站在全局的高度,统一收集、积累和分析总结各地资料;应该努力争取更多的组织病理材料供诊治分析和临床科研;需要定期修订诊断程序和治疗建议;强调“临床-影像-基因-病理”和“多学科团队(multi-disciplinary team, MDT)共诊共治”模式,以进一步提升我们的认知水平和丰富我们的防治经验。
  • [1] DISHOP M K. Dishop paediatric interstitial lung disease: classification and definitions. Paediatr Respir Rev,2011,12(4): 230–237. doi: 10.1016/j.prrv.2011.01.002
    [2] RICE A, TRAN-DANG M, BUSH A, et al. Diffuse lung disease in infancy and childhood: expanding the chILD classification. Histopathology,2013,63(6): 743–755. doi: 10.1111/his.12185
    [3] American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med,2002,165(2): 277–304. doi: 10.1164/ajrccm.165.2.ats01
    [4] TRAVIS W D, COSTABEL U, HANSELL D M, et al. An Official American Thoracic Society/European Respiratory Society Statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med,2013,188(6): 733–748. doi: 10.1164/rccm.201308-1483ST
    [5] DEUTSCH1 G H, YOUNG L R, DETERDING R R, et al. Diffuse lung disease in young children application of a novel classification scheme. Am J Respir Crit Care Med,2007,176(11): 1120–1128. doi: 10.1164/rccm.200703-393OC
    [6] CLEMENT A, NATHAN N, EPAUD R, et al. Interstitial lung diseases in children. Orphanet J Rare Dis, 2010, 5: 22[2021-03-06]. https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-5-22. doi: 10.1186/1750-1172-5-22.
    [7] 中华医学会儿科学分会呼吸学组全国儿童弥漫性实质性肺疾病/间质性肺疾病协作组. 中国儿童间质性肺疾病的临床研究. 中华儿科杂志,2011,49(10): 734–739. doi: 10.3760/cma.j.issn.0578-1310.2011.10.006
    [8] XU D, CHEN Z M, CHEN H Z, et al. Application of clinico-radiologic-pathologic diagnosis of diffuse parenchymal lung diseases in children in China. PLoS One, 2015, 10(1): e0116930[2021-03-06] https://doi.org/10.1371/journal.pone.0116930.
    [9] 中华医学会儿科学分会呼吸学组全国儿童弥漫性肺实质疾病/间质性肺疾病协作组. 儿童肺间质疾病诊断程序专家共识. 中华儿科杂志,2013,5l(2): 101–102. doi: 10.3760/cma.j.issn.0578-1310.2013.02.005
    [10] 陈杰华, 马红玲, 郑跃杰, 等. 21-三体综合征相关肺间质疾病一例并文献复习. 中华儿科杂志,2015,53(10): 771–774.
    [11] 郭润, 邹映雪, 翟嘉. 先天性肺囊性疾病96例临床分析. 中华儿科杂志,2020,58(1): 19–24. doi: 10.3760/cma.j.issn.0578-1310.2020.01.006
    [12] 农光民, 陈慧中. 关注婴幼儿肺间质疾病. 中华儿科杂志,2014,52(4): 241–243. doi: 10.3760/cma.j.issn.0578-1310.2014.04.001
    [13] 郑跃杰, 陈慧中. 基因缺陷引起的婴幼儿肺间质疾病. 中华儿科杂志,2014,52(4): 260–263. doi: 10.3760/cma.j.issn.0578-1310.2014.04.006
    [14] 黄莉, 王美娟, 陈正荣, 等. 肺表面活性物质蛋白C基因I73T突变相关性婴幼儿肺间质疾病一例并文献复习. 中华儿科杂志,2014,52(11): 846–850. doi: 10.3760/cma.j.issn.0578-1310.2014.11.012
    [15] 陈杰华, 赵德育, 安淑华, 等. 儿童肺表面活性物质蛋白C基因p.V39L突变三例临床分析. 中华儿科杂志,2017,55(6): 457–461. doi: 10.3760/cma.j.issn.0578-1310.2017.06.013
    [16] 鲍燕敏, 刘小兰, 刘晓莉, 等. 一种新的ABCA3基因复合杂合突变导致儿童弥漫性肺间质病一例. 中华儿科杂志,2017,55(11): 834–838. doi: 10.3760/cma.j.issn.0578-1310.2017.11.009
    [17] 邵亚楠. NKX2-1基因突变相关性新生儿呼吸衰竭1例并文献复习. 中外女性健康研究,2016,17: 1–3.
    [18] 王俊芳, 刘秀云, 殷菊, 等. 儿童间质性肺疾病表面活性物质功能障碍的基因突变研究. 中华实用儿科临床杂志,2018,33(4): 300–305. doi: 10.3760/cma.j.issn.2095-428X.2018.04.016
    [19] 刘静, 陈杰华, 王宇清, 等. 肺表面活性物质蛋白C基因218位点变异致婴幼儿肺间质疾病七例. 中华儿科杂志,2019,57(1): 21–26. doi: 10.3760/cma.j.issn.0578-1310.2019.01.007
    [20] CHEN J, NONG G, LIU X, et al. Genetic basis of surfactant dysfunction in Chinese children: A retrospective study. Pediatr Pulmonol,2019,54(8): 1173–1181. doi: 10.1002/ppul.24334
    [21] ZHANG G, CAO L. New mutations in the SLC7A7 gene of two chinese sisters with lysinurie protein intolerance. Pediatr Pulmonol,2017,52(11): E94–E96. doi: 10.1002/ppul.23760
    [22] 杨琴, 马红玲, 郑跃杰, 等. 以肺间质疾病为主要表现的赖氨酸尿性蛋白耐受不良一例. 中华儿科杂志,2019,57(1): 60–62. doi: 10.3760/cma.j.issn.0578-1310.2019.01.014
    [23] KURLAND G, DETERDING R R, HAGOOD J S, et al. An Official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy. Am J Respir Crit Care Med,2013,188(3): 376–394. doi: 10.1164/rccm.201305-0923ST
    [24] BUSH A, CUNNINGHAM S, DE BLIC J, et al. European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax,2015,70(11): 1078–1084. doi: 10.1136/thoraxjnl-2015-207349
    [25] 陈杰华, 鲍燕敏, 李志川, 等. 以肺间质疾病为主要表现的免疫缺陷病六例分析. 中华儿科杂志,2020,58(3): 228–232. doi: 10.3760/cma.j.issn.0578-1310.2020.03.013
    [26] TANG X, SHEN Y, ZHOU C, et al. Surfactant protein C dysfunction with new clinical insights for diffuse alveolar hemorrhage and autoimmunity. Pediatric Investigation,2019,3(4): 201–206. doi: 10.1002/ped4.12162
    [27] TANG X, LI H, LIU H, et al. Etiologic spectrum of interstitial lung diseases in Chinese children older than 2 years of age. Orphanet J Rare Dis,2020,15(1): 25–35. doi: 10.1186/s13023-019-1270-7
    [28] JOLY B S, SIGURET V, VEYRADIER A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med,2020,46(8): 1603–1606. doi: 10.1007/s00134-020-06088-1
    [29] 中华医学会儿科学分会呼吸学组全国儿童弥漫性肺实质疾病/肺间质疾病协作组. 儿童弥漫性肺实质疾病/肺间质疾病治疗建议(2018年版). 中华儿科杂志,2019,57(1): 5–8. doi: 10.3760/cma.j.issn.0578-1310.2019.01.004
    [30] 彭芸. 高分辨CT在儿童肺间质疾病诊断中的角色—我们需要知道什么? 中华儿科杂志,2013,51(2): 103–105. doi: 10.3760/cma.j.issn.0578-1310.2013.02.006
    [31] 吕丽嫒, 刘秀云, 江载芳, 等. 婴儿神经内分泌细胞增生症一例. 中华儿科杂志,2014,52(4): 317–318. doi: 10.3760/cma.j.issn.0578-1310.2014.04.018
    [32] 李颖, 麻锦敏. 宏基因组学测序技术在中重症感染中的临床应用专家共识(第一版). 中华危重病急救医学,2020,32(5): 531–536. doi: 10.3760/cma.j.cn121430-20200228-00095
    [33] CUNNINGHAM S, JAFFE A, YOUNG L R. Children’s interstitial and diffuse lung disease. Lancet Child Adolesc Health,2019,3(8): 568–577. doi: 10.1016/S2352-4642(19)30117-8
    [34] RAVAGLIA C, BONIFAZI M, WELLS A U, et al. Safety and diagnostic yield of transbronchial lung cryobiopsy in diffuse parenchymal lung diseases: A comparative study versus video-assisted thoracoscopic lung biopsy and a systematic review of the literature. Respiration,2016,91(3): 215–227. doi: 10.1159/000444089
    [35] 中华人民共和国卫生部医政司, 卫生部合理用药专家委员会. 国家抗微生物治疗指南(第2版). 北京: 人民卫生出版社, 2017: 141.
  • 加载中
计量
  • 文章访问数:  175
  • HTML全文浏览量:  66
  • PDF下载量:  50
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-05-17
  • 修回日期:  2021-07-31
  • 网络出版日期:  2021-12-06
  • 刊出日期:  2021-09-20

目录

    /

    返回文章
    返回